Human Vaccines Project Europe
Overview and Annual Report 2019/2020

General
On January 21, 2019, the Human Vaccines Project Europe was incorporated and established as a foundation in The Netherlands.

Name: Stichting Human Vaccines Project Europe
Chamber of commerce registration number (KvK): 73750805
RISN (fiscal information number): 859651551
Address: Stakman Bossestraat 78, 2203GL Noordwijk, The Netherlands
Email: fvandenboom@humanvaccinesproject.org
jme@procontrol.nl
Tel: +31 651 241 549
     +31 651 883 955

Goals and main activities of the Stichting:
Europe has an impressive history and track record in the biomedical sciences. The knowledge and expertise in the areas of virology, immunology, vaccinology, genomics, epidemiology, and more, are essential assets for the Human Vaccine Project to mobilize and involve stakeholders across the public and private sectors.
The purpose of the European Program is to contribute to the overall objective of the Human Vaccines Project to decode the human immune system and to accelerate the development of vaccines, immunotherapies and diagnostics to prevent, treat and cure important diseases.
The Stichting will focus on outreach, advocacy, fundraising, creating partnerships and consortia to shape and strengthen the European contribution to the global research program by:

• Establishing a network of leading European centers for human immunology and vaccinology networks centers and connecting them to the mission and activities of the Human Vaccines Project.
• Mobilizing financial support from the public, private and philanthropic sector.
• Advocating for scientific prioritization of the decoding of the immunome.
• Working together with government institutions, academia, industry and non-state actors – building champions and powerful alliances.

Board members per 31 December 2020:
Wayne C. Koff, Ph.D. (Chair)
Ted Schenkelberg, MBA/MPH (Secretary)
Jeroen van der Meer, M.Sc. (Treasurer)
Frans van den Boom, Ph.D./M.M.O.
Jaap Goudsmit, M.D./Ph.D.
Remuneration policy
The members of the board receive no remuneration for their work. They are entitled to reimbursement of the costs incurred by them in the performance of their duties.
Persons who are employed or employed for the benefit of the foundation can not be appointed as a member of the board.
In the future recruitment of employees, the salary of the director will be determined by the Board and will meet standards set by the government (Balkenende standard / WNT standard).

Financial responsibility
Financial year and annual documents (in accordance with article 9 of the articles of statutes).
- The financial year of the foundation is the same as the calendar year.
- The books of the foundation are closed at the end of each year. The treasurer draws up a balance sheet and a statement of income and expenditure for the financial year that has ended, which financial statements are presented to the board within two months after the end of the financial year.
- The board has the books of the foundation examined by an external expert who reports his findings to the board.
- The annual reports are adopted by the board after it has taken notice of the report issued by the external expert.
Annual Report 2019

Priorities
In 2018, outreach activities in Europe involved multiple countries (e.g. Germany, The Netherlands, Belgium, Spain, Norway), and the European Commission. Based on a mapping of interest in decoding the human immunome, existing relations with key stakeholders (e.g. government, industry, science organizations, funding agencies), it was decided to focus on Germany, The Netherlands, and the European Commission. Activities in other countries were opportunity based.

Germany
In January 2019, a first meeting was organized with the leading national research institutions and leading academic centers to discuss the possibility of a German Immunology and Vaccinology network. The established Working Group developed a white paper describing the priority areas for the German network as well as a draft Call to Action.

In addition, HVP met with representatives of the Ministries of Health and Science, as well as members of Parliament. Moreover, opportunities for raising support from HNWI’s, foundations and corporates were mapped.

HVP also liaised with media leaders to discuss supporting HVP and the German WG with resource mobilization and communications activities in Germany and Europe.

The Netherlands
Like Germany, The Netherlands has a strong scientific infrastructure; has a strong international position in biomedical research; and has a long-lasting commitment to global health. In January 2019, a meeting similar to the one in Germany was organized to discuss the contribution of The Netherlands in the global effort. Follow up meetings were organized with the leaders of 3 established consortia in the field of immunology by Health Holland, with Health Holland, ZonMw, the Ministries of Health, Economy and Climate and Foreign Affairs, and civil Society Organizations.

Input was provided to Health Holland Strategy 2019 – 2023, and HVP participated in the Economic mission to India, and contributed to a number of round tables on vaccines and therapeutics. Strong support by other institutions was given to HVP’s strategy. During the Tech Summit, HVP met with the Minister of Health, Bruno Bruins, and the Minister of International Development and Trade, Sigrid Kaag.

In 2019, HVP and the T.H. Chan School of Public Health at Harvard University launched the Human Immunomics Initiative. An key priority of the Initiative, was to involve community based cohort studies in better understanding of the immunology of ageing and – biological and chronological – health. Community based cohort studies in The Netherlands were identified as the first step in developing a global effort.

Finally, the Stichting Human Vaccines Project Europe was incorporated and registered in The Netherlands.
European Commission
HVP met with the Commission (DG Research and IMI) to discuss the feasibility of a specific call on decoding the human immunome with the support of HVP. Despite strong support for the concept, support for such a moonshot initiative was considered to be very complicated given the existing and agreed upon frameworks and funding regulations. However, it was strongly appreciated if HVP could respond to calls for proposals and work with European institutions to move this important effort forward. HVP took on this invitation by bringing together the partners in a consortium that developed a proposal under the EU - India joint call “Towards a next generation influenza vaccine to protect citizens worldwide”. The consortium, coordinated by Prof. Carlos Guzman at the Helmholtz Centre for Infection Research, is one of the 3 consortia that passed review and receive funding. The project will start in 2020.

Scientific outreach
The specific country activities were flanked by general scientific outreach efforts, in order to make the decoding of the human immune system a scientific priority, e.g.

- The ISGlobal Global Retreat, Barcelona
- Presentation at World Vaccine Congress, Lisbon
- Strategy meeting Topsector Life Science and Health, The Hague
- Systems Biology of Human Disease Meeting, Berlin
- Participation in Grand Challenges Meeting, Berlin

Financial report
During 2019, the Foundation was just being established and had no income or expenses, and activities were conducted under the Human Vaccines Project Inc. to launch the Foundation. No employees were recruited in 2019, nor were activities carried out by consultants who have an agreement with the foundation. Activities were executed by board members and consultants with the HVP Inc.

Governance
Board composition per 31 December 2019:
Wayne Koff – Chair
Theodore Schenkelberg – Treasurer
Frans van den Boom – Secretary
Jaap Goudsmit
COVID-19
The COVID-19 pandemic represented a significant programmatic and operational shift for the European Program, with significant redirection of policy, advocacy and scientific work to address the pandemic.

Within the restraints posed by the pandemic, we continued to reach out to potential donors, constituencies and partners. The impact of these efforts is limited in the sense that we have not been able to raise substantial resources for the HVP and its pillar programs, the Human Immunomics Initiative (HII), and the Covid Vaccine Initiative, but we have planted a number of seeds, and developed and strengthened existing relations.

Priorities
In 2020, outreach activities in Europe focused on Germany, The Netherlands, the European Commission and associated organizations (such as kENUP). Activities in other countries, such as Spain, Belgium, Denmark, Sweden and Switzerland were opportunity based. Outreach efforts targeted different constituencies: Foundations, Civil Society Organizations, Funding agencies, Governments, HNWI, Scientific Institutions, corporate organizations.

Activities and accomplishments

Germany
The working group to develop the concept of a German Network for Vaccinology and Immunology developed a White Paper. However, the CoV-SARS-2 pandemic made the working group partners focus on COVID-19. HVP together with the Looping Group continued to build (upon existing) relations to mobilize support from foundations and HNWI in Germany.

To build new communications platforms for HVP, HVP and Looping Group established new relationships with German stakeholder organizations like:

- The Atlantik-Brücke, where HVP held a joint virtual discussion for the Atlantik-Brücke members with the Anja Langenbucher, Director Europe der Bill & Melinda Gates Foundation, about pandemic preparedness
- Young Presidents Organization, where HVP gave a talk at their annual international members meeting
- Karl Lauterbach, Member of the German Parliament, who will support HVP with the outreach for the newly established Newborn Immunity Initiative
- In a nutshell, the internationally successful animation and production studio, about a possible serial in partnership with HVP

HVP will continue to grow these relationships and platforms in 2021.
Netherlands
Throughout 2020 we reached out to the Ministry of Health and research institutions to support an effort to link Dutch cohort studies with the academic laboratories in order to create an infrastructure that would contribute to the development of a predictive model for vaccination against infectious disease like COVID-19. The proposal linked Dutch institutions with the partnership between HVP and the T.H. Chan School of Public Health at Harvard University. HVP continues to reach out to both the academic centers, the community based cohorts and the government.

In addition, a number of proposals in which HVPE were submitted to funding organizations in The Netherlands (ZON-MW and Topsector LSH):
- Intranasal Administration of Hyperimmunoglobulin against COVID-19 (UMCU, Erasmus, Sanquin, Harvard): awarded
- The Trusted World of Corona (GoFair, TNO, LUMV, LU, Radboud MC, DTL Projects, Science and Technology BV, Euretos, Roche Nederland BV): awarded

An OpEd by Jaap Goudsmit, Bert Hofman and Frans van den Boom was published in ‘De Volkskrant’.

European Union
Two proposals were submitted to the European Commission. One in 2019 under the Horizon 2020 (INCENTIVE) and one under the IMI-2 program (FLORENCE).
- The INCENTIVE proposal has been awarded. Due to COVID-19, we requested a delay of the project to 1 August 2020. The EC accepted our request.
- FLORENCE has not been awarded.

The EC also announced two CfP’s on creating and / or building existing community based cohorts in the context of COVID-19. We reached out to the German National Cohort, the French Constance cohort, and the Italian IN-LiMes study. Although the interest in creating a European Immunomics Initiative was high, the deadline for preparing and submitting a solid proposal was too tight. However, we will continue to engage in conversations.

EDCTP
The European Developing Countries Clinical Trials Partnership also launched 2 CfP’s. Following a conversation with Michael Makanga, Executive Director EDCTP, we explored the possibility to submit a proposal with our partners in the US and S-Africa, but ultimately, we came to the conclusion that a joint proposal was not feasible.

KENUP
kENUP Foundation is a non-profit public benefit foundation supporting research-based innovation in the wider health industries for societal benefit. kENUP supports the development of scientific innovations into sustainable business propositions and makes
them financeable by public and private institutions, and civil society partners. In 2020, kENUP supported HVP in two ways:
1. kENUP signaled strong interest in funding HVP to develop a new for-profit branch to develop and protect its intellectual property and disseminate it for the public cause.
2. kENUP supported HVP with the application for public grants where KeNUP is involved in the selection process.

Switzerland, Denmark, Sweden
A number of foundations and HNWI’s were identified, and initial contact made.

Human Resources
The activities of the Stichting are executed by staff and consultants of the Human Vaccines Project Inc.

- Wayne Koff, President and CEO
- Theodore Schenkelberg, COO
- Jaap Goudsmit, CSO
- Frans van den Boom, Executive Director Europe (0,3 fte)
- Nadia Rozendaal, Senior Advisor Europe (0,3 fte), until 1 May 2020

Governance
Board composition per 31 December 2020:
Wayne Koff – Chair
Theodore Schenkelberg – Secretary
Jeroen van der Meer – Treasurer
Frans van den Boom
Jaap Goudsmit
Financial report 2020, in Euro

In 2020, the Stichting Human Vaccines Project did receive an advance payment on the INCENTIVE grant as well as an in-kind contribution from Looping Group.

Balance Sheet 31 December 2020

<table>
<thead>
<tr>
<th>Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Other receivables</td>
<td>0</td>
</tr>
<tr>
<td>Cash</td>
<td>278.032</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>278.032</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Special Purpose Fund INCENTIVE / Helmholtz Centre for Infection Research</td>
<td>274.537</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>3.495</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>278.032</strong></td>
</tr>
</tbody>
</table>

Statement of Operating Income and Expenditures

<table>
<thead>
<tr>
<th>Income</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Contribution Looping Group</td>
<td>63.405</td>
</tr>
<tr>
<td>Interest</td>
<td>17</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>63.422</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenditures</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Communications and strategic advise</td>
<td>63.405</td>
</tr>
<tr>
<td>Amounts Payable</td>
<td>3.472</td>
</tr>
<tr>
<td><strong>Total expenditures</strong></td>
<td><strong>66.877</strong></td>
</tr>
<tr>
<td>Negative result allocated to Special Purpose Fund</td>
<td>-3.455</td>
</tr>
<tr>
<td><strong>63.422</strong></td>
<td></td>
</tr>
</tbody>
</table>